BioDelivery Sciences International ( BioDelivery Sciences International)

Primary tabs

BioDelivery Sciences International's picture

Management

Contact Address

About BioDelivery Sciences International

BioDelivery Sciences ("BDSI"®) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. We are utilizing our novel and proprietary BioErodible MucoAdhesive (BEMA®) and other drug delivery technologies to develop and commercialize, either on our own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BioDelivery Sciences International press release, blog etc

Sun, 12/19/2021 - 20:32 BioDelivery Sciences Prevails in BELBUCA ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032
Sun, 12/19/2021 - 19:14 More events are coming soon.
Wed, 10/20/2021 - 19:15 BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer
Wed, 10/13/2021 - 20:58 BioDelivery Sciences International to Host ELYXYB Investor Day
Thu, 09/02/2021 - 19:22 BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences
Mon, 03/04/2019 - 23:46 BioDelivery Sciences Appoints Terry Coelho as Chief Financial Officer
Mon, 03/04/2019 - 00:10 BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA
Mon, 01/14/2019 - 19:06 BioDelivery Sciences to Present at the 2018 Janney Montgomery Scott Healthcare Conference
Mon, 01/14/2019 - 19:02 BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2018 Healthcare Conference
Mon, 01/14/2019 - 18:21 BioDelivery Sciences Announces Changes to its Executive Leadership Team
Mon, 01/14/2019 - 18:12 BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
Mon, 01/14/2019 - 16:52 BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA
Mon, 01/14/2019 - 16:31 BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA
Fri, 10/05/2018 - 16:41 BioDelivery Sciences to Host Institutional Investor and Analyst Day on Friday
Mon, 11/27/2017 - 05:14 BioDelivery Sciences Announces Ohio Workers Compensation Adding BELBUCA and BUNAVAIL to Formulary
Thu, 11/16/2017 - 05:04 BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference
Thu, 10/12/2017 - 04:02 BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva
Fri, 10/06/2017 - 09:06 BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence